Table 1 Baseline characteristics of the safety population
Anti-IL-13 | ||||
|---|---|---|---|---|
1 mg/kg (n = 8) | 5 mg/kg (n = 8) | 10 mg/kg (n = 3) | Placebo (n = 4) | |
Randomised, n | 8 | 8 | 3 | 4 |
Completed study, n (%) | 6 (75.0) | 7 (87.5) | 1 (33.3) | 2 (50.0) |
Sex, n (%) | ||||
Male | 8 (100) | 8 (100) | 2 (66.6) | 4 (100) |
Female | 0 | 0 | 1 (33.3) | 0 |
Age, years | ||||
Mean (SD) | 39.4 (9.1) | 34.6 (7.6) | 43.3 (14.5) | 40.0 (13.0) |
Range | 26-54 | 21-46 | 34-60 | 26-53 |
Race, n (%) | ||||
White | 8 (100) | 7 (87.5) | 3 (100) | 4 (100) |
Black | 0 | 1 (12.5) | 0 | 0 |
Weight, kg | ||||
Mean (SD) | 78.5 (11.2) | 88.3 (17.3) | 78.3 (20.7) | 76.0 (9.8) |
BMI, kg/m2 | ||||
Mean (SD) | 24.6 (3.0) | 26.3 (4.3) | 27.3 (3.1) | 23 (3.0) |
% predicted FEV1 | ||||
Mean (SD) | 95.3 (8.3) | 95.5 (9.8) | 90.7 (9.5) | 88.8 (4.6) |
FEV1 | ||||
Mean (SD) | 3.83 (0.54) | 4.17 (0.54) | 3.01 (1.35) | 3.64 (0.68) |
ICS dose, μg/d | ||||
Median (range) | 400 (200-400) | 400 (200-1000) | 200 (200-480) | |